Balance Sheet Concord Biotech Limited

Equities

CONCORDBIO

INE338H01029

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 01:39:20 2026-05-21 am EDT			5-day change	1st Jan Change
1,118.20 ^INR	+0.20%		-1.92%	-16.91%

Apr. 01	Concord Biotech Limited completed the acquisition of Celliimune Biotech Private Limited for 6.6 million.	CI
Feb. 13	Jefferies Adjusts Concord Biotech's Price Target to INR1,170 From INR1,290, Keeps at Hold	MT

2cd046c0128.ysGqm-f5ZVY2m6k0ysR1Fd4A46frNk4pNT8XvA2aKgI._7DkqKygDWFDyvtC-o0YdJBsup6Afxd6AHNeilLya1uMuP_oqa4XZFjw3g

Published financial data: CONCORD BIOTECH LIMITED

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: March	2021	2022	2023	2024	2025
Revenues	6.16B	7.13B	8.53B	10.17B	12B
Total Revenues	6.16B	7.13B	8.53B	10.17B	12B
Cost of Goods Sold, Total	1.17B	1.72B	1.92B	2.45B	4.32B
Gross Profit	4.99B	5.41B	6.61B	7.72B	7.68B
Selling General & Admin Expenses, Total	704M	957M	1.1B	1.23B	1.39B
Provision for Bad Debts	4.88M	-	-	-	-
Depreciation & Amortization - (IS)	275M	500M	540M	536M	544M
Other Operating Expenses	988M	1.66B	1.97B	2.09B	1.15B
Other Operating Expenses, Total	1.97B	3.12B	3.62B	3.85B	3.08B
Operating Income	3.02B	2.29B	2.99B	3.87B	4.6B
Interest Expense, Total	-5.23M	-54.84M	-45.1M	-25.52M	-5.29M
Interest And Investment Income	17.87M	47.87M	44.41M	30.41M	17.1M
Net Interest Expenses	12.64M	-6.97M	-695K	4.89M	11.81M
Income (Loss) On Equity Invest.	-4.49M	-36.38M	19.59M	33.71M	-13.22M
Currency Exchange Gains (Loss)	15.51M	63.59M	102M	64.8M	81.98M
Other Non Operating Income (Expenses)	11.25M	9.73M	62.04M	12.41M	43.54M
EBT, Excl. Unusual Items	3.06B	2.32B	3.18B	3.98B	4.73B
Gain (Loss) On Sale Of Investments	69.86M	52.3M	37.17M	141M	223M
Gain (Loss) On Sale Of Assets	-	-340K	-940K	119K	-2.25M
Insurance Settlements	29K	3.03M	6.51M	1.41M	9K
EBT, Incl. Unusual Items	3.13B	2.38B	3.22B	4.13B	4.95B
Income Tax Expense	778M	626M	819M	1.04B	1.23B
Earnings From Continuing Operations	2.35B	1.75B	2.4B	3.08B	3.72B
Net Income to Company	2.35B	1.75B	2.4B	3.08B	3.72B
Net Income - (IS)	2.35B	1.75B	2.4B	3.08B	3.72B
Net Income to Common Incl Extra Items	2.35B	1.75B	2.4B	3.08B	3.72B
Net Income to Common Excl. Extra Items	2.35B	1.75B	2.4B	3.08B	3.72B
Per Share Items
Net EPS - Basic	22.45	16.72	22.95	29.45	35.52
Basic EPS - Continuing Operations	22.45	16.72	22.95	29.45	35.52
Basic Weighted Average Shares Outstanding	105M	105M	105M	105M	105M
Net EPS - Diluted	22.45	16.72	22.95	29.45	35.52
Diluted EPS - Continuing Operations	22.45	16.72	22.95	29.45	35.52
Diluted Weighted Average Shares Outstanding	105M	105M	105M	105M	105M
Normalized Basic EPS	18.26	13.86	18.98	23.8	28.23
Normalized Diluted EPS	18.26	13.86	18.98	23.8	28.23
Dividend Per Share	6.74	5.12	6.83	8.75	10.7
Payout Ratio	2.43	40.31	22.31	23.19	24.63
Supplemental Items
EBITDA	3.29B	2.78B	3.52B	4.39B	5.13B
EBITA	3.05B	2.32B	3.03B	3.87B	4.6B
EBIT	3.02B	2.29B	2.99B	3.87B	4.6B
EBITDAR	3.29B	2.78B	3.52B	4.39B	-
Total Revenues (As Reported)	6.31B	7.36B	8.88B	10.51B	12.45B
Effective Tax Rate - (Ratio)	24.89	26.35	25.44	25.32	24.85
Total Current Taxes	757M	585M	795M	998M	1.19B
Total Deferred Taxes	23.39M	37.05M	23.82M	46.28M	39.5M
Normalized Net Income	1.91B	1.45B	1.99B	2.49B	2.95B
Interest on Long-Term Debt	3.99M	3.14M	1.82M	22.8M	4.76M
Non-Cash Pension Expense	121K	150K	647K	424K	306K
Supplemental Operating Expense Items
Marketing Expenses	9.33M	-	-	-	-
Selling and Marketing Expenses	9.33M	-	-	-	-
Research And Development Expense From Footnotes	-	-	328M	229M	274M
Net Rental Expense, Total	44K	20K	71K	200K	-
Imputed Operating Lease Interest Expense	2.61K	11.56K	54.48K	198K	-
Imputed Operating Lease Depreciation	41.39K	8.44K	16.52K	2.2K	-
Maintenance & Repair Expenses, Total	53.72M	79.08M	119M	156M	140M

Fiscal Period: March	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	51.44M	6.67M	34.99M	151M	9.04M
Short Term Investments	550M	872M	306M	228M	180M
Trading Asset Securities, Total	1.41B	735M	1.37B	2.44B	3.17B
Total Cash And Short Term Investments	2.01B	1.61B	1.71B	2.82B	3.35B
Accounts Receivable, Total	1.78B	2.32B	2.74B	3.5B	5.22B
Other Receivables	358M	273M	218M	160M	210M
Total Receivables	2.13B	2.59B	2.96B	3.66B	5.43B
Inventory	1.54B	1.95B	2.12B	2.08B	2.4B
Prepaid Expenses	45.44M	47.61M	55.18M	73.31M	73.91M
Other Current Assets, Total	345M	120M	433M	337M	100M
Total Current Assets	6.07B	6.33B	7.28B	8.96B	11.35B
Gross Property Plant And Equipment	6.5B	7.81B	9.53B	10.25B	11.33B
Accumulated Depreciation	-924M	-1.38B	-1.87B	-2.38B	-2.89B
Net Property Plant And Equipment	5.58B	6.44B	7.65B	7.86B	8.44B
Long-term Investments	3.66M	2.56M	1.25M	20.7M	228M
Other Intangibles, Total	64.17M	35.79M	1.98M	3.2M	11.22M
Other Long-Term Assets, Total	109M	327M	205M	156M	309M
Total Assets	11.83B	13.13B	15.14B	17.01B	20.34B
Liabilities
Accounts Payable, Total	464M	831M	938M	944M	1.13B
Accrued Expenses, Total	102M	131M	146M	168M	192M
Short-term Borrowings	50.99M	43.38M	-	-	3.81M
Current Portion of Long-Term Debt	250M	250M	250M	62.3M	-
Current Portion of Leases	13.01M	15.96M	1.47M	16.21M	19.58M
Current Income Taxes Payable	-	-	89.99M	54.94M	101M
Unearned Revenue Current, Total	-	32.72M	13.13M	-	-
Other Current Liabilities	177M	247M	480M	176M	394M
Total Current Liabilities	1.06B	1.55B	1.92B	1.42B	1.84B
Long-Term Debt	562M	312M	62.36M	-	-
Long-Term Leases	16.33M	3.11M	1.64M	18.87M	6.3M
Deferred Tax Liability Non Current	175M	210M	234M	281M	340M
Other Non Current Liabilities	20.98M	18.74M	22.97M	19.56M	28.2M
Total Liabilities	1.83B	2.1B	2.24B	1.74B	2.22B
Common Stock, Total	95.11M	95.11M	105M	105M	105M
Additional Paid In Capital	829M	829M	820M	820M	820M
Retained Earnings	9.07B	10.11B	11.98B	14.34B	17.2B
Total Common Equity	9.99B	11.03B	12.9B	15.27B	18.13B
Total Equity	9.99B	11.03B	12.9B	15.27B	18.13B
Total Liabilities And Equity	11.83B	13.13B	15.14B	17.01B	20.34B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	105M	105M	105M	105M	105M
ECS Total Common Shares Outstanding	105M	105M	105M	105M	105M
Book Value / Share	95.53	105.45	123.31	145.93	173.27
Tangible Book Value	9.93B	11B	12.9B	15.26B	18.12B
Tangible Book Value Per Share	94.91	105.11	123.29	145.9	173.17
Total Debt	893M	625M	315M	97.38M	29.69M
Net Debt	-1.12B	-989M	-1.39B	-2.72B	-3.32B
Debt Equivalent of Unfunded Proj. Benefit Obligation	2.21M	9.35M	5.77M	4.27M	5.8M
Debt Equivalent Oper. Leases	352K	160K	568K	1.6M	-
Equity Method Investments, Total	3.66M	-	-	20.59M	7.36M
Account Code - Inventory Valuation	5	5	5	5	5
Inventories - Raw Materials, Total	646M	808M	804M	633M	800M
Inventories - Work In Process, Total	683M	902M	1.13B	1.23B	1.34B
Inventories - Finished Goods, Total	201M	222M	148M	166M	210M
Inventories - Others	5.84M	19.41M	38.86M	45.71M	48.24M
Land - (BS)	547M	547M	547M	547M	630M
Buildings, Total	1.98B	2.23B	2.46B	2.58B	3.55B
Machinery, Total	3.77B	4.29B	4.79B	4.98B	6.62B
Full Time Employees	-	1.18K	-	1.38K	1.57K
Accumulated Allowance for Doubtful Accounts (Supple)	11.27M	7.81M	8.73M	13.91M	31.75M

Fiscal Period: March	2021	2022	2023	2024	2025
Net Income	2.35B	1.75B	2.4B	3.08B	3.72B
Depreciation & Amortization - CF	243M	467M	507M	533M	541M
Amortization of Goodwill and Intangible Assets - (CF)	31.04M	32.4M	32.4M	2.9M	3.01M
Depreciation & Amortization, Total	274M	499M	539M	535M	544M
Amortization of Deferred Charges, Total - (CF)	1.54M	1.55M	1.39M	489K	126K
(Gain) Loss From Sale Of Asset	-	340K	940K	-119K	2.25M
(Gain) Loss on Sale of Investments - (CF)	-69.86M	-52.3M	-37.17M	-141M	-223M
(Income) Loss On Equity Investments - (CF)	4.49M	36.38M	-19.59M	-33.71M	13.22M
Provision and Write-off of Bad Debts	4.6M	-3.46M	924K	6.69M	17.84M
Other Operating Activities, Total	-7.52M	64.53M	120M	17.31M	81.91M
Change In Accounts Receivable	64.99M	-528M	-431M	-787M	-1.71B
Change In Inventories	-424M	-415M	-172M	43.61M	-317M
Change In Accounts Payable	-225M	365M	98.81M	-113M	221M
Change in Other Net Operating Assets	-304M	357M	-18.42M	44.06M	96.54M
Cash from Operations	1.67B	2.07B	2.48B	2.65B	2.45B
Capital Expenditure	-2.04B	-1.56B	-1.45B	-857M	-1.11B
Sale of Property, Plant, and Equipment	-	560K	253K	1.75M	1.99M
Investment in Marketable and Equity Securities, Total	88.68M	395M	-185M	-719M	-598M
Other Investing Activities, Total	1.07M	41.39M	55.85M	27.73M	108M
Cash from Investing	-1.95B	-1.12B	-1.58B	-1.55B	-1.6B
Short Term Debt Issued, Total	50.99M	-	-	-	-
Long-Term Debt Issued, Total	520M	-	-	-	-
Total Debt Issued	571M	-	-	-	-
Short Term Debt Repaid, Total	-	-7.61M	-	-	-
Long-Term Debt Repaid, Total	-198M	-267M	-268M	-265M	-67.45M
Total Debt Repaid	-198M	-274M	-268M	-265M	-67.45M
Common Dividends Paid	-57.06M	-705M	-536M	-715M	-915M
Common & Preferred Stock Dividends Paid	-57.06M	-705M	-536M	-715M	-915M
Other Financing Activities, Total	-1.58M	-22.26M	-5.41M	-12.58M	-4.84M
Cash from Financing	314M	-1B	-809M	-992M	-988M
Miscellaneous Cash Flow Adjustments	-	-	-66.32M	-	-
Net Change in Cash	27.36M	-44.77M	28.32M	116M	-142M
Supplemental Items
Cash Interest Paid	1.58M	53.15M	37.76M	26.5M	6.33M
Cash Income Tax Paid (Refund)	752M	608M	703M	1.03B	1.09B
Levered Free Cash Flow	-834M	189M	503M	1.18B	926M
Unlevered Free Cash Flow	-831M	223M	531M	1.19B	929M
Change In Net Working Capital	951M	154M	429M	903M	1.38B
Net Debt Issued / Repaid	372M	-274M	-268M	-265M	-67.45M

Fiscal Period: March	2021	2022	2023	2024	2025
Profitability
Return on Assets	17.8	11.47	13.24	15.04	15.4
Return on Total Capital	19.77	12.7	15.05	16.92	17.16
Return On Equity %	26.55	16.64	20.06	21.88	22.26
Return on Common Equity	26.55	16.64	20.06	21.88	22.26
Margin Analysis
Gross Profit Margin %	81.03	75.89	77.49	75.93	64.03
SG&A Margin	11.42	13.42	12.93	12.1	11.58
EBITDA Margin %	53.3	38.97	41.28	43.13	42.72
EBITA Margin %	49.54	32.58	35.48	38.06	38.36
EBIT Margin %	49.03	32.12	35.1	38.03	38.34
Income From Continuing Operations Margin %	38.11	24.54	28.14	30.3	30.97
Net Income Margin %	38.11	24.54	28.14	30.3	30.97
Net Avail. For Common Margin %	38.11	24.54	28.14	30.3	30.97
Normalized Net Income Margin	31	20.34	23.28	24.48	24.61
Levered Free Cash Flow Margin	-13.54	2.65	5.9	11.58	7.72
Unlevered Free Cash Flow Margin	-13.48	3.13	6.23	11.74	7.74
Asset Turnover
Asset Turnover	0.58	0.57	0.6	0.63	0.64
Fixed Assets Turnover	1.31	1.19	1.21	1.31	1.47
Receivables Turnover (Average Receivables)	3.41	3.48	3.37	3.26	2.75
Inventory Turnover (Average Inventory)	0.88	0.99	0.94	1.16	1.93
Short Term Liquidity
Current Ratio	5.74	4.08	3.79	6.3	6.17
Quick Ratio	3.92	2.71	2.43	4.55	4.77
Operating Cash Flow to Current Liabilities	1.58	1.34	1.29	1.87	1.33
Days Sales Outstanding (Average Receivables)	106.89	104.87	108.22	112.18	132.49
Days Outstanding Inventory (Average Inventory)	413.31	370.19	387.11	314.19	189.22
Average Days Payable Outstanding	134.75	110.74	154.27	143.28	81.7
Cash Conversion Cycle (Average Days)	385.45	364.33	341.06	283.09	240.01
Long Term Solvency
Total Debt/Equity	8.93	5.66	2.45	0.64	0.16
Total Debt / Total Capital	8.2	5.36	2.39	0.63	0.16
LT Debt/Equity	5.79	2.86	0.5	0.12	0.03
Long-Term Debt / Total Capital	5.32	2.71	0.48	0.12	0.03
Total Liabilities / Total Assets	15.49	15.96	14.79	10.23	10.89
EBIT / Interest Expense	577.67	41.76	66.39	151.56	869.27
EBITDA / Interest Expense	629.98	50.86	78.34	172.54	971.97
(EBITDA - Capex) / Interest Expense	239.28	22.5	46.17	138.96	761.93
Total Debt / EBITDA	0.27	0.22	0.09	0.02	0.01
Net Debt / EBITDA	-0.34	-0.35	-0.39	-0.62	-0.65
Total Debt / (EBITDA - Capex)	0.71	0.51	0.15	0.03	0.01
Net Debt / (EBITDA - Capex)	-0.89	-0.8	-0.67	-0.77	-0.82
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	20.31	15.56	19.67	19.2	18.01
Gross Profit, 1 Yr. Growth %	33.46	8.2	22.19	16.8	15.16
EBITDA, 1 Yr. Growth %	53.5	-15.48	26.78	24.38	16.9
EBITA, 1 Yr. Growth %	57.39	-23.97	30.31	27.7	18.96
EBIT, 1 Yr. Growth %	55.79	-24.26	30.74	28.98	18.97
Earnings From Cont. Operations, 1 Yr. Growth %	38.89	-25.53	37.25	28.33	20.62
Net Income, 1 Yr. Growth %	38.89	-25.53	37.25	28.33	20.62
Normalized Net Income, 1 Yr. Growth %	51.98	-24.11	36.94	25.36	18.62
Diluted EPS Before Extra, 1 Yr. Growth %	38.89	-25.52	37.25	28.33	20.62
Accounts Receivable, 1 Yr. Growth %	-3.26	30.79	17.91	27.71	49.21
Inventory, 1 Yr. Growth %	38.1	27.02	8.81	-2.05	15.25
Net Property, Plant and Equip., 1 Yr. Growth %	46.42	15.38	18.95	2.74	7.34
Total Assets, 1 Yr. Growth %	25.73	11.01	15.33	12.33	19.61
Tangible Book Value, 1 Yr. Growth %	28.93	10.74	17.29	18.34	18.69
Common Equity, 1 Yr. Growth %	29.75	10.39	16.93	18.34	18.74
Cash From Operations, 1 Yr. Growth %	7.76	24.37	19.29	7.91	-7.89
Capital Expenditures, 1 Yr. Growth %	31.49	-23.84	-6.7	-40.94	29.74
Levered Free Cash Flow, 1 Yr. Growth %	-	-122.71	166.37	132.77	-21.34
Unlevered Free Cash Flow, 1 Yr. Growth %	-	-126.96	138.1	123.47	-22.12
Dividend Per Share, 1 Yr. Growth %	63.87	-24.05	33.4	28.11	22.29
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-	17.96	17.6	19.43	18.6
Gross Profit, 2 Yr. CAGR %	-	20.23	14.99	19.47	7.81
EBITDA, 2 Yr. CAGR %	-	13.93	3.51	25.65	20.58
EBITA, 2 Yr. CAGR %	-	9.42	-0.46	29.09	23.25
EBIT, 2 Yr. CAGR %	-	8.65	-0.49	29.95	23.87
Earnings From Cont. Operations, 2 Yr. CAGR %	-	1.71	1.1	32.71	24.42
Net Income, 2 Yr. CAGR %	-	1.71	1.1	32.71	24.42
Normalized Net Income, 2 Yr. CAGR %	-	7.4	1.94	31.03	21.94
Diluted EPS Before Extra, 2 Yr. CAGR %	-	1.7	1.11	32.71	24.42
Accounts Receivable, 2 Yr. CAGR %	-	12.48	24.18	22.71	38.04
Inventory, 2 Yr. CAGR %	-	32.44	17.57	3.24	6.25
Net Property, Plant and Equip., 2 Yr. CAGR %	-	29.98	17.15	10.55	5.02
Total Assets, 2 Yr. CAGR %	-	18.14	13.15	13.82	15.92
Tangible Book Value, 2 Yr. CAGR %	-	19.49	13.97	17.81	18.51
Common Equity, 2 Yr. CAGR %	-	19.68	13.61	17.64	18.54
Cash From Operations, 2 Yr. CAGR %	-	15.75	22	12.93	-0.3
Capital Expenditures, 2 Yr. CAGR %	-	0.01	-15.7	-25.77	-12.46
Levered Free Cash Flow, 2 Yr. CAGR %	-	-	-22.23	149.69	35.3
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	-	-19.88	131.27	31.91
Dividend Per Share, 2 Yr. CAGR %	-	11.56	0.66	30.73	25.16
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-	-	18.53	18.13	18.96
Gross Profit, 3 Yr. CAGR %	-	-	20.88	15.59	12.4
EBITDA, 3 Yr. CAGR %	-	-	18.06	10.09	22.66
EBITA, 3 Yr. CAGR %	-	-	15.98	8.21	25.62
EBIT, 3 Yr. CAGR %	-	-	15.57	8.55	26.18
Earnings From Cont. Operations, 3 Yr. CAGR %	-	-	12.39	9.47	28.55
Net Income, 3 Yr. CAGR %	-	-	12.39	9.47	28.55
Normalized Net Income, 3 Yr. CAGR %	-	-	16.46	9.22	26.75
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-	12.39	9.47	28.55
Accounts Receivable, 3 Yr. CAGR %	-	-	14.26	25.35	30.98
Inventory, 3 Yr. CAGR %	-	-	24.05	10.62	7.1
Net Property, Plant and Equip., 3 Yr. CAGR %	-	-	26.19	12.14	9.47
Total Assets, 3 Yr. CAGR %	-	-	17.2	12.88	15.72
Tangible Book Value, 3 Yr. CAGR %	-	-	18.75	15.41	18.11
Common Equity, 3 Yr. CAGR %	-	-	18.76	15.17	18
Cash From Operations, 3 Yr. CAGR %	-	-	17.05	16.75	5.52
Capital Expenditures, 3 Yr. CAGR %	-	-	-2.28	-25.13	-10.58
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	-	12.28	69.88
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	-	12.98	60.89
Dividend Per Share, 3 Yr. CAGR %	-	-	18.41	9.08	27.85
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-	-	-	-	18.56
Gross Profit, 5 Yr. CAGR %	-	-	-	-	15.47
EBITDA, 5 Yr. CAGR %	-	-	-	-	19.09
EBITA, 5 Yr. CAGR %	-	-	-	-	18.87
EBIT, 5 Yr. CAGR %	-	-	-	-	18.85
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-	-	17.06
Net Income, 5 Yr. CAGR %	-	-	-	-	17.06
Normalized Net Income, 5 Yr. CAGR %	-	-	-	-	18.62
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-	-	17.06
Accounts Receivable, 5 Yr. CAGR %	-	-	-	-	23.24
Inventory, 5 Yr. CAGR %	-	-	-	-	16.59
Net Property, Plant and Equip., 5 Yr. CAGR %	-	-	-	-	17.25
Total Assets, 5 Yr. CAGR %	-	-	-	-	16.68
Tangible Book Value, 5 Yr. CAGR %	-	-	-	-	18.66
Common Equity, 5 Yr. CAGR %	-	-	-	-	18.67
Cash From Operations, 5 Yr. CAGR %	-	-	-	-	9.57
Capital Expenditures, 5 Yr. CAGR %	-	-	-	-	-6.49
Dividend Per Share, 5 Yr. CAGR %	-	-	-	-	21.07